MAXIMIZING THE POTENTIAL OF IBRUTINIB: MULTI-FACTOR OPTIMIZATION AND INTERACTION ANALYSIS FOR IMPROVED NANOBUBBLE FORMULATION AND BIOAVAILABILITY PERFORMANCE

B. VIJAYA LAXMI; D. V. R. N. BHIKSHAPATHI; V. V. RAJESHAM; P. POORNIMA; P. SANDHYA; G. ARJUN

doi:10.22159/ijap.2025v17i5.54081

Authors

B. VIJAYA LAXMI Bir Tikandrajit University, Canchipur, Imphal West-795003, Manipur, India
D. V. R. N. BHIKSHAPATHI Bir Tikandrajit University, Canchipur, Imphal West-795003, Manipur, India. Department of Pharmaceutics, Teegala Ram Reddy College of Pharmacy, Meerpet, Hyderabad-500097, Telangana, India
V. V. RAJESHAM Department of Pharmacology, CMR College of Pharmacy, Kandlakoya (V) Medchal (MandD), Hyderabad-501401, Telangana, India https://orcid.org/0000-0003-2809-4048
P. POORNIMA Siddhartha Institute of Pharmacy, Korremula Road, Narepally, Ghatkesar, Hyderabad-501301, Telangana, India
P. SANDHYA Shadan Women’s College of Pharmacy, Khairatabad, Hyderabad-500004, Telangana, India
G. ARJUN Department of Pharmaceutics, Teegala Ram Reddy College of Pharmacy, Meerpet, Hyderabad-500097, Telangana, India

DOI:

https://doi.org/10.22159/ijap.2025v17i5.54081

Keywords:

Box-behnken design, Ibrutinib, Mantle cell lymphoma, Nanobubbles, PLGA

Abstract

Objective: Ibrutinib (IBR), a v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor, faces solubility challenges as a Biopharmaceutics Classification System Class II drug. The objective of this was to formulate IBR-loaded polylactic-co-glycolic acid (PLGA) nanobubbles (NBs) using the solvent evaporation method with ultrasound assistance.

Methods: IBR-PLGA nanobubble optimization was achieved by implementing a four-factor, three-level BBD and a total of 29 experimental runs, including three replicated centre points, comprised the Box-Behnken design (BBD). The formulated NBs were characterized for particle size, zeta potential (ZP), drug entrapment efficiency (EE), compatibility studies in vitro studies, and stability studies along with in vivo studies in rats.

Results: The optimized NBs displayed a particle size of 130±13.3 nm, ZP of-23.0±0.89 mV and EE of 49.14±1.32. In vitro studies revealed superior drug release (98%) with ultrasound versus plain drugs (20%). Fourier Transform Infrared Spectroscopy and Differential Scanning Calorimetry studies confirmed no drug-polymer interaction. Scanning Electron Microscopy images showcased uniform spherical nano-sized particles. Stability studies indicated no significant changes after 1 mo. The Cmax increased 4.35-fold (p<0.01), and AUC0-t enhanced 8.13-fold (p<0.001) compared to plain IBR with statistical significance.

Conclusion: Results indicate that IBR-loaded PLGA NBs could be effective in sustaining its release for a prolonged period for the treatment of breast cancer. Targeted medicine delivery through passive targeting via enhanced permeability and retention is made possible by the potential use of NBs in the creation of ultrasonic-responsive combinations.

References

1. Pandey V, Pandey T. Chitosan functionalized nanobubbles for precision oncology: advances in targeted cancer therapeutics. J Mater Chem B. 2024;12(43):11076-88. doi: 10.1039/d4tb01930j, PMID 39385619.

2. Estupinan HY, Berglof A, Zain R, Smith CI. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021 Mar 9;9:630942. doi: 10.3389/fcell.2021.630942, PMID 33777941.

3. Eisenmann ED, Fu Q, Muhowski EM, Jin Y, Uddin ME, Garrison DA. Intentional modulation of ibrutinib pharmacokinetics through CYP3A inhibition. Cancer Res Commun. 2021 Nov;1(2):79-89. doi: 10.1158/2767-9764.crc-21-0076, PMID 34950932.

4. Piskin S, Sevim Akan H, Armutcu C, Uzun L. Collagen nanobubbles as efficient carriers for targeted controlled release of ibrutinib. J Mater Chem B. 2024;12(46):12050-61. doi: 10.1039/d4tb01608d, PMID 39441099.

5. Jin J, Yang L, Chen F, Gu N. Drug delivery system based on nanobubbles. Interdisciplinary Materials. 2022;1(4):471-94. doi: 10.1002/idm2.12050.

6. Qiu Q, Lu M, Li C, Luo X, Liu X, Hu L. Novel self-assembled ibrutinib phospholipid complex for potently peroral delivery of poorly soluble drugs with pH-dependent solubility. AAPS PharmSciTech. 2018 Aug;19(8):3571-83. doi: 10.1208/s12249-018-1147-4, PMID 30209789.

7. Rangaraj N, Pailla SR, Chowta P, Sampathi S. Fabrication of ibrutinib nanosuspension by quality by design approach: intended for enhanced oral bioavailability and diminished fast fed variability. AAPS PharmSciTech. 2019 Aug;20(8):326. doi: 10.1208/s12249-019-1524-7, PMID 31659558.

8. Rangaraj N, Pailla SR, Shah S, Prajapati S, Sampathi S. QbD aided development of ibrutinib loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Deliv Transl Res. 2020 Oct;10(5):1476-94. doi: 10.1007/s13346-020-00803-7, PMID 32519202.

9. Darji AA, Bharadia PD. Chronic myelogenous leukemia: a review and update of current and future therapy. Int J Pharm Pharm Sci. 2016 Jul;8(7):35-46.

10. Jin J, Yang L, Chen F, Gu N. Drug delivery system based on nanobubbles. Interdisciplinary Materials. 2022 Dec;1(4):471-94. doi: 10.1002/idm2.12050.

11. Rocha CV, Goncalves V, Da Silva MC, Banobre Lopez M, Gallo J. PLGA-based composites for various biomedical applications. Int J Mol Sci. 2022 Feb;23(4):2034. doi: 10.3390/ijms23042034, PMID 35216149.

12. Shakya G, Cattaneo M, Guerriero G, Prasanna A, Fiorini S, Supponen O. Ultrasound responsive microbubbles and nanodroplets: a pathway to targeted drug delivery. Adv Drug Deliv Rev. 2024 Mar;206:115178. doi: 10.1016/j.addr.2023.115178, PMID 38199257.

13. Ponnaganti M, Kishore Babu A. Preparation, characterization and evaluation of chitosan nanobubbles for the targeted delivery of ibrutinib. Int J Pharm Pharm Sci. 2021 Aug;8(6):1-12.

14. Kumar MK, Prakash DJ, Rao VV. Chitosan nanobubbles development and evaluation for the delivery of sunitinib an anticancer agent. Int J App Pharm. 2022 Nov;14(6):58-67. doi: 10.22159/ijap.2022v14i6.45821.

15. Arafath AA, Jayakar B. Enhancement of oral bioavailability via solid lipid nanoparticles of anticancer drug dasatinib an in vitro cytotoxicity and pharmacokinetic study. Asian J Pharm Clin Res. 2019 Jun;12(6):143-5. doi: 10.22159/ajpcr.2019.v12i6.33135.

16. Hernandez C, Abenojar EC, Hadley J, De Leon AC, Coyne R, Perera R. Sink or float? Characterization of shell-stabilized bulk nanobubbles using a resonant mass measurement technique. Nanoscale. 2019 Jan;11(3):851-5. doi: 10.1039/c8nr08763f, PMID 30601524.

17. Zhou L, Wang S, Zhang L, Hu J. Generation and stability of bulk nanobubbles: a review and perspective. Curr Opin Colloid Interface Sci. 2021 Sep;53(1):101439. doi: 10.1016/j.cocis.2021.101439.

18. Reddy KS, Bhikshapathi D, Kumar JP. Unlocking dabrafenib’s potential: a quality by design (QBD) journey to enhance permeation and oral bioavailability through nanosponge formulation. Braz J Pharm Sci. 2025;61(1):e24209. doi: 10.1590/s2175-97902025e24209.

19. Kyzas GZ, Mitropoulos AC. From bubbles to nanobubbles. Nanomaterials (Basel). 2021 Oct;11(10):2592. doi: 10.3390/nano11102592, PMID 34685033.

20. Batchelor DV, Armistead FJ, Ingram N, Peyman SA, McLaughlan JR, Coletta PL. The influence of nanobubble size and stability on ultrasound-enhanced drug delivery. Langmuir. 2022;38(45):13943-54. doi: 10.1021/acs.langmuir.2c02303, PMID 36322191.

21. Rasmussen MK, Pedersen JN, Marie R. Size and surface charge characterization of nanoparticles with a salt gradient. Nat Commun. 2020 Apr;11(1):2337. doi: 10.1038/s41467-020-15889-3, PMID 32393750.

22. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018 Apr;10(2):57. doi: 10.3390/pharmaceutics10020057, PMID 29783687.

23. Alheshibri M, Al Baroot A, Shui L, Zhang M. Nanobubbles and nanoparticles. Curr Opin Colloid Interface Sci. 2021 Dec;55(43):101470. doi: 10.1016/j.cocis.2021.101470.

24. SU C, Ren XJ, Nie F, Li T, LV W, Li H. Current advances in ultrasound combined nanobubbles for cancer targeted therapy: a review of the current status and future perspectives. RSC Adv. 2021 May;11(21):12915-28. doi: 10.1039/d0ra08727k, PMID 35423829.

25. Margheritelli S. Exploring chitosan shelled nanobubbles to improve HER2+immunotherapy via dendritic cell targeting. Drug Deliv Transl Res. 2022;12(11):2590-603.

26. Laxmi BV, Bhikshapathi D, Sailaja Rao P. Optimization and enhancement of oral bioavailability of dabrafenib as nanobubbles using quality by design approach. Pharm Sci. 2025 Jan;31(1):xx-xx. doi: 10.34172/PS.2024.32.

27. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018 Jun 25;10(2):57. doi: 10.3390/pharmaceutics10020057, PMID 29783687.

28. Prabhakar A, Banerjee R. Nanobubble liposome complexes for diagnostic imaging and ultrasound-triggered drug delivery in cancers: a theranostic approach. ACS Omega. 2019;4(13):15567-80. doi: 10.1021/acsomega.9b01924, PMID 31572858.

29. Alheshibri M, Al Baroot A, Shui L, Zhang M. Nanobubbles and nanoparticles. Curr Opin Colloid Interface Sci. 2021 Oct;55(43):101470. doi: 10.1016/j.cocis.2021.101470.

30. Begum MY, Gudipati PR. Formulation and evaluation of dasatinib-loaded solid lipid nanoparticles. Int J Pharm Pharm Sci. 2018 Dec;10(12):14-20. doi: 10.22159/ijpps.2018v10i12.27567.

31. Su C, Ren XJ, Nie F, Li T, Lv W, Li H. Current advances in ultrasound combined nanobubbles for cancer targeted therapy: a review of the current status and future perspectives. RSC Adv. 2021 May 6;11(21):12915-28. doi: 10.1039/d0ra08727k, PMID 35423829.

32. Foudas AW, Kosheleva RI, Favvas EP, Kostoglou M, Mitropoulos AC, Kyzas GZ. Fundamentals and applications of nanobubbles: a review. Chem Eng Res Des. 2023 Jan;189(4):64-86. doi: 10.1016/j.cherd.2022.11.013.

33. Cho CH, Shin HJ, Singh B, Kim K, Park MH. Assessment of sub-200-nm nanobubbles with ultra-high stability in water. Appl Water Sci. 2023 Jul;13(7):1-10. doi: 10.1007/s13201-023-01950-1.

34. Meegoda JN, Aluthgun Hewage S, Batagoda JH. Stability of nanobubbles. Environ Eng Sci. 2018 Nov;35(11):1216-27. doi: 10.1089/ees.2018.0203.

35. Aliabouzar M, Quesada C, Chan ZQ, Fowlkes JB, Franceschi RT, Putnam AJ. Acoustic droplet vaporization for on-demand modulation of microporosity in smart hydrogels. Acta Biomater. 2023 Jul 1;164:195-208. doi: 10.1016/j.actbio.2023.04.037, PMID 37121372.

36. Palanati M, Bhikshapathi DV. Development, characterization and evaluation of entrectinib nanosponges loaded tablets for oral delivery. Int J App Pharm. 2023 Nov-Dec;15(6):269-81. doi: 10.22159/ijap.2023v15i6.49022.

37. Wang X. Development of folate conjugated nanobubbles for targeted ultrasound imaging and drug delivery in ovarian cancer. Front Pharmacol. 2022;13:835678.